SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Calcium channel-modulator-1

Cat. No.: HY-U00135

CAS No.: 136941-70-3

Molecular Formula: $C_{26}H_{24}Cl_2N_2O_7S$

Molecular Weight: 579.45

Target: Calcium Channel

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 12.5 mg/mL (21.57 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7258 mL	8.6289 mL	17.2577 mL
5 mM	0.3452 mL	1.7258 mL	3.4515 mL
10 mM	0.1726 mL	0.8629 mL	1.7258 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1.25 mg/mL (2.16 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.25 mg/mL (2.16 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Calcium channel-modulator-1 is a calcium channel modulator; blocks aortic contraction with an IC_{50} of 0.8 μM.

IC_{50} & Target

IC50: 0.8 μM (Aortic contraction)[1]

In Vivo

Oral administration of Calcium channel-modulator-1 (20 mg/kg) causes a 35-37% decrease in systolic blood pressure in spontaneously hypertensive rats. However, iv administration of Calcium channel-modulator-1 to anesthetized spontaneously hypertensive rats causes a decrease in blood pressure which was more pronounced and long-lasting than that of nifedipine[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sunkel CE, et al. Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators. J Med Chem. 1992 Jun 26;35(13):2407-14.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA